Article: Bio-Vascular Confirms Guidance for Fiscal 2001; Sees Revenue Growth Of 27 Percent and EPS Growth of 271 Percent.

ST. PAUL, Minn., Oct. 31 /PRNewswire/ --

Bio-Vascular, Inc., (Nasdaq: BVAS) expects to meet its guidance given on August 22, 2001 for its fiscal year ending today, October 31. This includes consolidated revenue growth of 27 percent and fully diluted EPS growth of 271 percent. This equates to revenue of near $28 million and fully diluted earnings per share of approximately 19 cents.

"Business is excellent and we expect it will continue to be excellent," said Karen G. Larson, Bio-Vascular president and chief executive officer.

In fiscal 2000, the company reported consolidated revenue of $21,926,000 and consolidated net income of $589,000, or ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!